<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Achieving hemostasis after cardiac surgery with cardiopulmonary bypass</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Achieving hemostasis after cardiac surgery with cardiopulmonary bypass</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Achieving hemostasis after cardiac surgery with cardiopulmonary bypass</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kamrouz Ghadimi, MD, MHSc, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ian J Welsby, BSc, MBBS, FRCA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan B Mark, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 09, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4234942865"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Blood and coagulation management are key components of anesthetic management for cardiac surgical procedures requiring cardiopulmonary bypass (CPB).</p><p>This topic discusses management of bleeding after weaning from CPB during a cardiac surgical procedure. Administration of protamine to reverse systemic anticoagulation after CPB is discussed separately. (See  <a class="medical medical_review" href="/d/html/140293.html" rel="external">"Protamine: Administration and management of adverse reactions during cardiovascular procedures", section on 'Protamine administration after cardiopulmonary bypass'</a>.)</p><p>Strategies employed before and during CPB to avoid or minimize blood loss and transfusion of blood components are discussed separately. (See  <a class="medical medical_review" href="/d/html/94297.html" rel="external">"Blood management and anticoagulation for cardiopulmonary bypass"</a>.)</p><p>General principles for perioperative blood management and indications for intraoperative transfusion are discussed in separate topics. (See  <a class="medical medical_review" href="/d/html/94347.html" rel="external">"Perioperative blood management: Strategies to minimize transfusions"</a> and  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors"</a>.)</p><p class="headingAnchor" id="H490143528"><span class="h1">REVERSAL OF ANTICOAGULATION ACTIVITY</span></p><p class="headingAnchor" id="H2021590821"><span class="h2">Reversal of heparin anticoagulation</span><span class="headingEndMark"> — </span>Systemic anticoagulation with heparin is reversed with protamine after weaning from cardiopulmonary bypass (CPB). Techniques for protamine administration, dosing considerations, and recognition, treatment, and prevention of adverse reactions to protamine are discussed separately. (See  <a class="medical medical_review" href="/d/html/140293.html" rel="external">"Protamine: Administration and management of adverse reactions during cardiovascular procedures", section on 'Protamine administration after cardiopulmonary bypass'</a>.)</p><p class="headingAnchor" id="H2548712313"><span class="h2">Management of bivalirudin anticoagulation</span><span class="headingEndMark"> — </span>In rare cases, anticoagulation with <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> is used as an alternative to anticoagulation with heparin (eg, in patients with known severe protamine allergy or heparin-induced thrombocytopenia [HIT] when HIT antibodies are present). (See  <a class="medical medical_review" href="/d/html/118004.html" rel="external">"Management of heparin-induced thrombocytopenia (HIT) during cardiac or vascular surgery"</a>.)</p><p><a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">Bivalirudin</a> has a half-life of approximately 45 minutes in normothermic patients with normal kidney function; thus, its anticoagulant effects typically resolve within approximately two hours of administration of the last dose. If bleeding is excessive in the postbypass period, more rapid offset of action may be achieved with combinations of therapies that reduce circulating blood levels and eliminate the agent (eg, dilution with blood component replacement, plasmapheresis with plasma exchange, hemodialysis) [<a href="#rid1">1</a>]. Of note, there is no reversal agent for bivalirudin.</p><p class="headingAnchor" id="H834494919"><span class="h1">ACHIEVING HEMOSTASIS AND MANAGEMENT OF BLEEDING</span><span class="headingEndMark"> — </span>After weaning from cardiopulmonary bypass (CPB) and reversing anticoagulation, excessive bleeding may occur due to both surgical and nonsurgical causes [<a href="#rid2">2</a>]. Hemostasis depends primarily on surgical control of bleeding sites, achieving and maintaining normothermia, and selective administration of blood components as necessary. Significant blood loss may occur during any surgical procedure involving the heart and great vessels. The need for full systemic anticoagulation during CPB and adequacy of reversal after weaning from CPB, hemodilution due to fluid priming of the extracorporeal circuit, residual hypothermia after CPB, as well as fibrinolysis, platelet dysfunction, and coagulation factor consumption during CPB may all influence ability to achieve hemostasis [<a href="#rid3">3,4</a>].</p><p>Bleeding necessitating transfusion occurs commonly after cardiac surgery with CPB, although transfusion rates vary widely among institutions (10 to 90 percent) [<a href="#rid5">5-7</a>]. In general, patients who are transfused have worse outcomes than those without transfusions, but this is a strong association rather than cause-and-effect [<a href="#rid8">8,9</a>].</p><p>Preoperative risk factors for perioperative bleeding and blood transfusion after CPB include advanced age, decreased preoperative red blood cell (RBC) mass (eg, small body size, preoperative anemia), existing coagulopathy, and complex or redo operations [<a href="#rid7">7,10-13</a>]. (See  <a class="medical medical_review" href="/d/html/94347.html" rel="external">"Perioperative blood management: Strategies to minimize transfusions", section on 'Preoperative strategies'</a>.)</p><p>Intraoperative causes of excessive bleeding after CPB include inadequate surgical hemostasis, loss of platelets and coagulation factors due to high volume cell saver use, presence of residual heparin, and effects of CPB such as hemodilution, hypothermic coagulopathy, coagulopathy due to platelet activation (and consumption), and hyperfibrinolysis induced by the extracorporeal circuit. (See  <a class="medical medical_review" href="/d/html/94297.html" rel="external">"Blood management and anticoagulation for cardiopulmonary bypass", section on 'Effects of cardiopulmonary bypass on hemostasis'</a> and <a class="local">'Reversal of heparin anticoagulation'</a> above.)</p><p class="headingAnchor" id="H3005606314"><span class="h2">Fastidious surgical hemostasis</span><span class="headingEndMark"> — </span>The primary means to achieve hemostasis after CPB is meticulous surgical technique including systematic intraoperative checking of potential surgical sites of bleeding, apparent or hidden. In a meta-analysis of patients requiring mediastinal re-exploration for bleeding or cardiac tamponade after cardiac surgery, a surgical site of bleeding was identified in two-thirds of cases [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H4238568214"><span class="h2">Maintenance of normothermia</span><span class="headingEndMark"> — </span>Mild-to-moderate hypothermia is induced in most patients to provide neurologic and cardiac protection for many patients undergoing CPB, while deep hypothermia to temperatures as low as 16 to 18°C is employed for selected patients undergoing elective circulatory arrest. (See  <a class="medical medical_review" href="/d/html/103812.html" rel="external">"Management of cardiopulmonary bypass", section on 'Management during cooling and hypothermia'</a> and  <a class="medical medical_review" href="/d/html/94292.html" rel="external">"Anesthesia for aortic surgery with hypothermia and elective circulatory arrest in adult patients", section on 'Considerations for anesthetic management'</a>.)</p><p>Rewarming during CPB and subsequent maintenance of normothermia in the postbypass period are necessary because hypothermia is associated with coagulopathy due to impairment of platelet aggregation and reduced activity of clotting enzymes [<a href="#rid15">15-17</a>]. This combination of platelet and enzyme impairment reduces clot formation and increases perioperative blood loss and the need for blood transfusion [<a href="#rid18">18-20</a>].</p><p>Active warming techniques must be employed to achieve normothermia during the rewarming phase of CPB, then to maintain normothermia during the postbypass and postoperative periods. Details regarding warming strategies are available in other topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/103812.html" rel="external">"Management of cardiopulmonary bypass", section on 'Management during rewarming and weaning'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/94588.html" rel="external">"Perioperative temperature management", section on 'Active warming devices'</a>.)</p><p></p><p class="headingAnchor" id="H473723553"><span class="h2">Use of transfusion algorithms</span><span class="headingEndMark"> — </span>We use goal-directed protocols or algorithms to guide transfusion decisions based on measurement of hemoglobin or hematocrit (HCT), as well as assessment of specific abnormalities of hemostasis using standard laboratory tests  (<a class="graphic graphic_algorithm graphicRef131934" href="/d/graphic/131934.html" rel="external">algorithm 1</a>), and/or point-of-care (POC) tests of hemostasis [<a href="#rid2">2</a>]. This practice is consistent with guidelines from several professional societies for both cardiac and noncardiac surgical cases [<a href="#rid6">6,7,10,21-24</a>]. Use of such transfusion protocols and algorithms to guide decision-making can avoid or reduce unnecessary transfusions of blood components including RBCs, Fresh Frozen Plasma (FFP), platelets, and Cryoprecipitate  (<a class="graphic graphic_table graphicRef53854" href="/d/graphic/53854.html" rel="external">table 1</a>) [<a href="#rid2">2,6,7,22,25-36</a>]. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Use of a transfusion algorithm or protocol'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoglobin or HCT levels </strong>– We check hemoglobin or HCT levels following weaning from CPB, then approximately every 30 minutes, or more frequently in a profusely bleeding patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Standard laboratory coagulation tests </strong>– Standard laboratory tests include prothrombin time (PT) and international normalized ratio (INR), activated partial thromboplastin time (aPTT), fibrinogen level, and platelet count. Clinically significant bleeding at any time during the postbypass period should trigger repeat evaluation of standard laboratory tests  (<a class="graphic graphic_algorithm graphicRef131934" href="/d/graphic/131934.html" rel="external">algorithm 1</a>), and/or POC tests as noted below, to aid decision-making regarding which therapies will likely reverse coagulation abnormalities.</p><p></p><p class="bulletIndent1">Although platelet transfusions are typically guided by platelet count, tests of platelet function can be performed. Detecting a residual effect of P2Y<sub>12</sub> inhibitors may be helpful in patients with mild-to-moderate microvascular bleeding. However, most platelet function tests are inaccurate after CPB due to dilutional changes and platelet activation [<a href="#rid37">37</a>]. In addition, these tests may not be useful in an actively bleeding patient since accuracy depends on a relatively normal platelet count. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests"</a> and  <a class="medical medical_review" href="/d/html/4433.html" rel="external">"Platelet function testing"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>POC tests of hemostatic function </strong>– We employ POC viscoelastic coagulation tests in addition to standard laboratory coagulation tests to guide transfusion therapy, similar to the recommendations in professional society guidelines for centers with these POC tests. Commonly used viscoelastic coagulation tests are thromboelastography (TEG), rotational thromboelastometry (ROTEM), or sonorheometry  (<a class="graphic graphic_table graphicRef74954" href="/d/graphic/74954.html" rel="external">table 2</a>) [<a href="#rid6">6,7,38</a>]. Viscoelastic testing can either supplement standard laboratory tests of hemostatic function or in experienced hands, can stand alone and may be superior to standard tests and/or clinical judgment because assessments of coagulopathy are more rapid and contain much more information on the coagulation defect. Therefore, responses to interventions such as transfusion of blood components, or administration of hemostatic agents can be more immediately assessed [<a href="#rid39">39</a>]. Details and evidence supporting regarding use of transfusion algorithms guided by viscoelastic testing are available in a separate topic. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Point-of-care tests'</a>.)</p><p></p><p class="headingAnchor" id="H3679050110"><span class="h3">Transfusion of red blood cells</span><span class="headingEndMark"> — </span>We generally transfuse RBCs if hemoglobin is &lt;7 to 8 g/dL (or HCT &lt;21 to 24 percent) [<a href="#rid10">10,11</a>], similar to professional society practice guidelines for blood conservation during cardiac surgery  (<a class="graphic graphic_algorithm graphicRef131934" href="/d/graphic/131934.html" rel="external">algorithm 1</a>) [<a href="#rid6">6,7,10,11,40-42</a>]. However, we may target a higher hemoglobin in a patient with poorly controlled hemorrhage or signs of worsening myocardial or other organ ischemia. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Cardiac surgery'</a> and  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Red blood cells'</a> and  <a class="medical medical_review" href="/d/html/7931.html" rel="external">"Massive blood transfusion"</a>.)</p><p>When transfusion is necessary, available recovered blood is returned first, followed by reinfusion of blood units harvested via normovolemic hemodilution, then transfusion of allogeneic RBCs [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/d/html/7937.html" rel="external">"Surgical blood conservation: Intraoperative blood salvage"</a> and  <a class="medical medical_review" href="/d/html/94297.html" rel="external">"Blood management and anticoagulation for cardiopulmonary bypass", section on 'Acute normovolemic hemodilution'</a>.)</p><p class="headingAnchor" id="H585885303"><span class="h3">Transfusion of other blood components</span></p><p class="headingAnchor" id="H2760550228"><span class="h4">Plasma</span><span class="headingEndMark"> — </span>Generally, fresh frozen plasma (FFP) or any other form of plasma product is transfused only in the presence of active bleeding and PT/INR or aPTT &gt;1.5 normal ( (<a class="graphic graphic_algorithm graphicRef131934" href="/d/graphic/131934.html" rel="external">algorithm 1</a>) [<a href="#rid10">10,43</a>]. Transfusion of plasma is also included in massive transfusion protocols, usually in a 1:1:1 ratio with transfusion of RBC units and platelets [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Plasma'</a> and  <a class="medical medical_review" href="/d/html/7931.html" rel="external">"Massive blood transfusion", section on 'Component ratio (1:1:1)'</a>.)</p><p>Outside of massive transfusion protocols, FFP is not appropriate in the absence of significant bleeding and laboratory evidence of coagulopathy [<a href="#rid6">6,40,43</a>].</p><p class="headingAnchor" id="H3296313366"><span class="h4">Platelets</span><span class="headingEndMark"> — </span>Transfusion of platelets is reserved for patients with platelet count &lt;100,000/microL  (<a class="graphic graphic_algorithm graphicRef131934" href="/d/graphic/131934.html" rel="external">algorithm 1</a>), or platelet dysfunction (eg, due to residual anti-platelet drug effect after administration of antiplatelet medication, particularly P2Y<sub>12</sub> receptor inhibitors such as <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a>, and <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a>), but only if there is clinically significant and ongoing microvascular bleeding [<a href="#rid6">6,7</a>].</p><p>Thrombocytopenia is common in the immediate postbypass period due to a combination of hemodilution, platelet loss (eg, due to persistent surgical bleeding, adherence to the CPB circuit surface, or consumption as coagulation occurs), and accelerated clearance caused by thrombin-mediated platelet activation. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Platelets'</a> and  <a class="medical medical_review" href="/d/html/1585.html" rel="external">"Early noncardiac complications of coronary artery bypass graft surgery", section on 'Antiplatelet agents'</a>.)</p><p>Transfusion of platelets is also included in massive transfusion protocols. (See  <a class="medical medical_review" href="/d/html/7931.html" rel="external">"Massive blood transfusion", section on 'Component ratio (1:1:1)'</a>.)</p><p>Rarely, thrombocytopenia occurs as a manifestation of acute disseminated intravascular coagulation (DIC) after CPB (see  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Acute DIC'</a>), or due to heparin-induced thrombocytopenia (HIT). (See  <a class="medical medical_review" href="/d/html/118004.html" rel="external">"Management of heparin-induced thrombocytopenia (HIT) during cardiac or vascular surgery"</a>.)</p><p class="headingAnchor" id="H21448972"><span class="h4">Cryoprecipitate versus fibrinogen concentrate</span><span class="headingEndMark"> — </span>While administration of Cryoprecipitate or <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> will not always resolve coagulopathic bleeding after CPB, we aggressively correct acquired hypofibrinogenemia if fibrinogen concentration is &lt;150 mg/dL as a component of a multifactorial transfusion algorithm in patients with clinically significant bleeding [<a href="#rid25">25</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Congenital or acquired hypofibrinogenemia are clear indications for administering a fibrinogen product. Other indications are discussed separately.</p><p></p><p class="bulletIndent1">The European Association for Cardio-Thoracic Surgery and the European Association of Cardiothoracic Anaesthesiology recommend fibrinogen administration for patients with low fibrinogen levels and persistent microvascular bleeding [<a href="#rid41">41</a>]. However, these groups do not recommend prophylactic fibrinogen administration since available data do not support beneficial effects such as reduction of postoperative bleeding or transfusion risks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of product</strong> – If available, we prefer <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> rather than Cryoprecipitate or FFP to treat hypofibrinogenemia because fibrinogen concentrate has less risk of infection and transfusion reactions compared with Cryoprecipitate or plasma [<a href="#rid6">6,7,45-52</a>]. However, the choice of product is based on which product is stocked at the institution. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Cryoprecipitate or fibrinogen concentrate'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">Fibrinogen concentrate</a> is typically selected to treat hypofibrinogenemia in continental Europe and Canada due to its lower risk of infection and transfusion reactions since it is not an allogeneic blood product. Cryoprecipitate is not typically available in these regions [<a href="#rid52">52-55</a>]. Although fibrinogen concentrate may be more expensive than Cryoprecipitate in the United States and the United Kingdom, the overall cost may be lower, as demonstrated in a cost-effectiveness analysis from Canadian health care system in cardiac surgical patients with active bleeding and acquired hypofibrinogenemia [<a href="#rid56">56</a>]. The increasing use of fibrinogen concentrates as a source of fibrinogen in surgical patients and dosing considerations are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Fibrinogen concentrate'</a>.)</p><p></p><p class="bulletIndent1">Cryoprecipitate is often used to treat hypofibrinogenemia in the United States and the United Kingdom because of its wider availability and lower cost in these regions compared with <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> [<a href="#rid45">45</a>]. Dosing considerations for Cryoprecipitate are discussed separately. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Cryoprecipitate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting evidence</strong> – Randomized trials suggest outcomes are similar with Cryoprecipitate and fibrinogen concentrates.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The 2019 FIBRES (<strong>FIB</strong>rinogen <strong>RE</strong>plenishment in <strong>S</strong>urgery) trial was a well-conducted trial that randomly assigned 735 individuals experiencing clinically significant bleeding and hypofibrinogenemia after cardiac surgery to receive <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> (4 grams) or Cryoprecipitate (10 units) [<a href="#rid55">55</a>]. There was no difference in transfusion of additional blood components (red blood cells, platelets, and plasma).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2014 trial randomly assigned 63 children &lt;7 years undergoing elective cardiac surgery who had diffuse bleeding after heparin neutralization and fibrinogen &lt;100 mg/dL to receive <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> (60 mg/kg) or Cryoprecipitate (10 mL/kg) [<a href="#rid57">57</a>]. There were no significant differences in length of hospital stay, length of time in the intensive care unit, bleeding or thrombotic complications, or major adverse events. The fibrinogen group had a lower rate of postoperative transfusions that barely met statistical significance (87 versus 100 percent; p = 0.046).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2013 trial randomly assigned 61 individuals undergoing aortic valve replacement surgery with cardiopulmonary bypass to receive <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> (median dose, 8 grams) or placebo, along with standard transfusions for bleeding [<a href="#rid49">49</a>]. Compared with controls, the patients assigned to fibrinogen concentrate received fewer allogeneic transfusions (median, 13 versus 2; total avoidance of transfusion, 45 versus 0 percent). Adverse events were similar in both arms. This trial demonstrated that fibrinogen concentrate reduced allogeneic transfusions, but it was small and did not show a reduction in adverse events; comparison between fibrinogen concentrate and Cryoprecipitate was not performed.</p><p></p><p class="bulletIndent1">However, as opposed to cryoprecipitate, <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> does not contain von Willebrand factor (VWF), or factor VIII. Thus, it may not be ideal for all cardiac surgical patients with hypofibrinogenemia and coagulopathy due to acquired von Willebrand syndrome, particularly after a prolonged duration of CPB [<a href="#rid45">45,52</a>]. (See  <a class="medical medical_review" href="/d/html/94297.html" rel="external">"Blood management and anticoagulation for cardiopulmonary bypass", section on 'Effects of cardiopulmonary bypass on hemostasis'</a> and  <a class="medical medical_review" href="/d/html/110531.html" rel="external">"Acquired von Willebrand syndrome"</a>.)</p><p></p><p class="bulletIndent1">Furthermore, in nonbleeding patients, efficacy of prophylactic <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> has not been demonstrated and is not recommended [<a href="#rid52">52,53,58,59</a>].</p><p></p><p class="headingAnchor" id="H3399609928"><span class="h2">Clotting factors and hemostatic agents</span><span class="headingEndMark"> — </span>Clotting factors may be used to treat excessive bleeding in selected patients during the postbypass period. <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">Fibrinogen concentrate</a> administration for hypofibrinogenemia is discussed above. (See <a class="local">'Cryoprecipitate versus fibrinogen concentrate'</a> above.)</p><p class="headingAnchor" id="H2068683011"><span class="h3">Prothrombin complex concentrate products</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prothrombin complex concentrates (PCCs) </strong>– A 4-factor unactivated PCC is approved for use in emergency surgery in patients chronically taking <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> or another vitamin K antagonist. (See  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Urgent surgery/procedure'</a> and  <a class="medical medical_review" href="/d/html/7925.html" rel="external">"Plasma derivatives and recombinant DNA-produced coagulation factors", section on 'PCCs'</a>.)</p><p></p><p class="bulletIndent1">Off-label intraoperative administration of unactivated 4-factor or 3-factor PCC products has been evaluated for patients with intractable coagulopathy and diffuse bleeding after CPB  (<a class="graphic graphic_table graphicRef94210" href="/d/graphic/94210.html" rel="external">table 3</a>), although data regarding intraoperative safety of PCC products in cardiac surgical patients are limited [<a href="#rid6">6,7,46,60-70</a>]. A 2022 randomized trial compared administration of PCC 15 International Units/kg versus FFP 10 to 15 mL/kg in 100 patients with excessive microvascular bleeding after CPB accompanied by a POC PT &gt;16.6 seconds and INR &gt;1.6 [<a href="#rid66">66</a>]. Overall efficacy and safety were comparable for PCC and FFP, with improved correction of PT and INR in patients receiving PCC. The numbers of total intraoperative RBC transfusions and total postoperative RBC transfusions were not statistically different between the groups. Other randomized and observational studies in cardiac surgical patients have also noted reductions in blood transfusions in patients receiving PCC compared with those receiving FFP, as discussed in a separate topic [<a href="#rid65">65,69-71</a>]. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Unactivated PCC'</a>.)</p><p></p><p class="bulletIndent1">Before considering administration of a PCC product in a cardiac surgical patient with intractable microvascular bleeding, other common causes of bleeding after CPB should be sought and treated (eg, surgical sources, thrombocytopenia, low levels of fibrinogen, platelet dysfunction, DIC) [<a href="#rid67">67,72</a>]. Dosing is discussed separately. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Unactivated PCC'</a>.).</p><p></p><p class="bulletIndent1">PCC products are generally avoided in patients with DIC or heparin-induced thrombocytopenia (HIT). Risk for thromboembolic events may be more likely with repeat or excessive dosing of both 4-factor and 3-factor PCCs, and may extend well into the postoperative period [<a href="#rid69">69,73</a>]. (See  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'PCC risks'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activated PCCs </strong>– In contrast with unactivated PCCs, activated PCC (factor eight inhibitor bypassing activity [FEIBA]) contains activated factor VII  (<a class="graphic graphic_table graphicRef94210" href="/d/graphic/94210.html" rel="external">table 3</a>) [<a href="#rid67">67</a>]. FEIBA has a greater prothrombotic risk compared with unactivated PCC products and is only rarely used [<a href="#rid72">72,74</a>]. (See  <a class="medical medical_review" href="/d/html/7925.html" rel="external">"Plasma derivatives and recombinant DNA-produced coagulation factors", section on 'PCCs'</a> and  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Activated PCC'</a>.)</p><p></p><p class="headingAnchor" id="H386007415"><span class="h3">Recombinant activated factor VII</span><span class="headingEndMark"> — </span>Recombinant activated factor VII (rFVIIa) is licensed for prevention of surgical bleeding in patients with hemophilia who have developed an inhibitor to factor VIII or factor IX. (See  <a class="medical medical_review" href="/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B", section on 'Inhibitors'</a>.).</p><p>In rare instances of severe intractable life-threatening coagulopathic bleeding after CPB, off-label administration of rFVIIa has been used in attempts to achieve bleeding cessation and reduce transfusion requirements [<a href="#rid6">6,7,75-77</a>]. However, high thromboembolism rates &gt;20 percent (including myocardial infarction) with mortality &gt;30 percent have been described in retrospective evaluations of registries for refractory bleeding cases [<a href="#rid78">78,79</a>]. (See  <a class="medical medical_review" href="/d/html/1341.html" rel="external">"Recombinant factor VIIa: Administration and adverse effects", section on 'Off-label uses'</a> and  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Recombinant activated factor VII (rFVIIa)'</a>.)</p><p>Similar to off-label use of PCCs (see <a class="local">'Prothrombin complex concentrate products'</a> above), other primary causes of coagulopathy should always be sought and treated before considering administration of rFVIIa. Failure to treat the primary coagulation defect increases the likelihood of an inadequate response to the initial dose of rFVIIa [<a href="#rid78">78-80</a>], and may encourage use of higher doses that are more likely to cause thrombosis [<a href="#rid81">81,82</a>]. (See  <a class="medical medical_review" href="/d/html/1341.html" rel="external">"Recombinant factor VIIa: Administration and adverse effects", section on 'General approach to administration'</a>.)</p><p>Although optimal dosing and timing of rFVIIa doses for this off-label use for intractable bleeding after CPB is unknown, we employ a cautious dosing strategy in the rare instances that rFVIIa is administered (eg, small incremental doses of 10 mcg/kg given approximately every 15 minutes). Note that this US Food and Drug Administration (FDA)-approved dose is far less than the 90 to 120 mcg/kg used in hemophilia. Thromboembolic complications are more likely with dose escalation, or in the presence of stagnant flow or presence of devices such as extracorporeal membrane oxygenation (ECMO) [<a href="#rid6">6</a>]. One study in cardiac surgical patients reported cessation of bleeding after administration of incremental aliquots of rFVIIa, at a median dose of 13.3 mcg/kg [<a href="#rid75">75</a>]. Regarding timing of administration, a randomized study reported smaller total doses were necessary if rFVIIa was administered earlier in the postbypass period when no more than one RBC unit had been transfused (12.2 [9.7-16.4] mcg/kg), while higher doses were necessary if five or more units had been transfused (18.0 [11.8-29.0] mcg/kg) [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H3853593209"><span class="h3">Antifibrinolytic agents</span><span class="headingEndMark"> — </span>Timing for discontinuing administration of a prophylactic antifibrinolytic agent (eg, epsilon-aminocaproic acid [EACA] or <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> [TXA]) that is usually initiated in the prebypass period varies among institutions. If active bleeding necessitating transfusion persists, we typically continue administration of the antifibrinolytic agent throughout the post bypass period and for several postoperative hours. (See  <a class="medical medical_review" href="/d/html/140949.html" rel="external">"Intraoperative use of antifibrinolytic agents", section on 'Use of antifibrinolytic agents in cardiac surgery'</a>.)</p><p class="headingAnchor" id="H2442415261"><span class="h3">Desmopressin</span><span class="headingEndMark"> — </span>Routine use of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (DDAVP) in cardiac surgical patients is not warranted [<a href="#rid6">6,24,46</a>]. In selected patients with acquired platelet defects due to uremia or acquired von Willebrand syndrome (eg, due to chronic aortic stenosis or presence of a left ventricular assist device), we administer intravenous (IV) DDAVP 0.3 mcg/kg in the postbypass period, but only if persistent microvascular bleeding is evident [<a href="#rid6">6,7,46,83-86</a>]. DDAVP should be infused slowly over 15 to 30 minutes to avoid vasodilation. Tachyphylaxis occurs after the initial dose and during the initial three to five days of administration. (See  <a class="medical medical_review" href="/d/html/1947.html" rel="external">"Uremic platelet dysfunction", section on 'Details of DDAVP administration'</a> and  <a class="medical medical_review" href="/d/html/110531.html" rel="external">"Acquired von Willebrand syndrome", section on 'Treatment of acute bleeding'</a>.)</p><p>Some clinicians administer IV DDAVP to reduce blood loss in cardiac surgical patients with intractable microvascular bleeding due to platelet dysfunction suspected to be caused by hypothermia, acidosis, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> use, and/or the effects of CPB. Although very limited data suggest its benefit in such cases [<a href="#rid6">6,87-90</a>], studies are inconsistent [<a href="#rid91">91,92</a>]. Two 2017 meta-analyses of the efficacy of DDAVP in patients undergoing cardiac or noncardiac surgery noted only small reductions in perioperative blood loss and volume of RBC transfusions compared with placebo, with quality of evidence rated as low [<a href="#rid89">89,90</a>].</p><p>Possible adverse side effects of DDAVP include hypertension, hypotension, flushing, fluid overload, hyponatremia (which may cause seizures if close attention to free water restriction is not used), and rare thrombotic events  (<a class="graphic graphic_table graphicRef110532" href="/d/graphic/110532.html" rel="external">table 4</a>).</p><p class="headingAnchor" id="H2138212883"><span class="h1">EARLY POSTOPERATIVE MANAGEMENT</span></p><p class="headingAnchor" id="H3216991548"><span class="h2">Management of bleeding and coagulopathy</span><span class="headingEndMark"> — </span>Close monitoring for bleeding continues in the postoperative period. Return to the operating room for mediastinal re-exploration and intervention may be necessary based on the rate and presumed location of bleeding, as well as the surgeon's assessment of potential for a surgical cause [<a href="#rid93">93,94</a>]. Excessive bleeding requiring mediastinal re-exploration has been associated with adverse outcomes that include mortality, need for mechanical circulatory support, stroke, acute kidney injury, sternal wound infection, prolonged mechanical ventilation, and increased costs [<a href="#rid95">95,96</a>].</p><p>Fastidious surgical hemostasis is the most important measure to prevent postoperative blood transfusions and surgical re-exploration. Timely preoperative cessation of anticoagulants and antiplatelet drugs is also helpful [<a href="#rid97">97</a>]. (See <a class="local">'Fastidious surgical hemostasis'</a> above and  <a class="medical medical_review" href="/d/html/94347.html" rel="external">"Perioperative blood management: Strategies to minimize transfusions", section on 'Management of medications affecting hemostasis'</a>.)</p><p>Similar to the intraoperative period, we use a hemoglobin threshold of &lt;7 to 8 g/dL to initiate decisions to transfuse red blood cells (RBCs), but may target a higher hemoglobin in a patient with poorly controlled hemorrhage or signs of worsening myocardial or other organ ischemia. As an alternative, one randomized trial reported use of central venous oxygen saturation (SvO<sub>2</sub>) measurements ≤65 percent as the trigger for RBC administration [<a href="#rid98">98</a>]. Transfusion of fewer RBC units was reported with this target, compared with use of a fixed hemoglobin target of &lt;9 g/dL (odds ratio [OR] 0.03, 95% CI 0-0.15). (See <a class="local">'Transfusion of red blood cells'</a> above.)</p><p>We obtain viscoelastic tests and laboratory data, including coagulation tests and hemoglobin measurements, to guide transfusion decisions [<a href="#rid26">26,36,41,42,69,99</a>]. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'General principles for transfusion decisions'</a>.)</p><p class="headingAnchor" id="H2181853498"><span class="h2">Management of anemia</span><span class="headingEndMark"> — </span>Postoperative anemia is common due to exacerbation of preexisting anemia, blood loss during surgery, and excessive postoperative phlebotomies [<a href="#rid43">43,100</a>]. Management strategies are noted in the algorithm and discussed separately  (<a class="graphic graphic_algorithm graphicRef131161" href="/d/graphic/131161.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/d/html/94347.html" rel="external">"Perioperative blood management: Strategies to minimize transfusions", section on 'Management of postoperative anemia'</a>.)</p><p class="headingAnchor" id="H3527192390"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120167.html" rel="external">"Society guideline links: Transfusion and patient blood management"</a> and  <a class="medical medical_society_guidelines" href="/d/html/118172.html" rel="external">"Society guideline links: Management of cardiopulmonary bypass"</a>.)</p><p class="headingAnchor" id="H1699357341"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reversal of heparin anticoagulation with protamine </strong>–<strong> </strong>Systemic heparin anticoagulation is reversed with protamine, as discussed in a separate topic. (See  <a class="medical medical_review" href="/d/html/140293.html" rel="external">"Protamine: Administration and management of adverse reactions during cardiovascular procedures", section on 'Protamine administration after cardiopulmonary bypass'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reversal of </strong><strong>bivalirudin</strong><strong> anticoagulation </strong>–<strong> </strong><a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">Bivalirudin</a> is a rarely used alternative anticoagulant agent. Its anticoagulant effects typically resolve within two hours. If necessary, more rapid offset of action may be achieved with therapies that reduce circulating blood levels and eliminate the agent (eg, blood product replacement, hemodialysis, plasmapheresis with plasma exchange). (See <a class="local">'Management of bivalirudin anticoagulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of intraoperative bleeding</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgical hemostasis </strong>–<strong> </strong>The primary means to achieve hemostasis is meticulous surgical technique. (See <a class="local">'Fastidious surgical hemostasis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maintain normothermia </strong>–<strong> </strong>Active warming techniques to achieve and maintain normothermia are employed as necessary. (See <a class="local">'Maintenance of normothermia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Use a transfusion algorithm </strong>–<strong> </strong>We use a goal-directed protocol or algorithm to guide transfusion decisions, based on measurement of hemoglobin or hematocrit (HCT), assessment of specific abnormalities of hemostasis using standard laboratory tests of hemostatic function  (<a class="graphic graphic_algorithm graphicRef131934" href="/d/graphic/131934.html" rel="external">algorithm 1</a>), as well as point-of care viscoelastic tests of coagulation if available (eg, thromboelastography [TEG], rotational thromboelastometry [ROTEM], or sonorheometry  (<a class="graphic graphic_table graphicRef74954" href="/d/graphic/74954.html" rel="external">table 2</a>)). (See <a class="local">'Use of transfusion algorithms'</a> above.)</p><p></p><p class="bulletIndent2">Transfusion decisions for individual blood components include  (<a class="graphic graphic_table graphicRef53854" href="/d/graphic/53854.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Red blood cells (RBCs) </strong>– We typically transfuse RBCs for hemoglobin &lt;7 to 8 g/dL (or HCT &lt;21 to 24 percent). Available recovered blood is returned first, followed by reinfusion of blood units harvested via normovolemic hemodilution, then transfusion of allogeneic RBCs. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Cardiac surgery'</a> and  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Red blood cells'</a> and <a class="local">'Transfusion of red blood cells'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Plasma </strong>– Plasma products are transfused when prothrombin time (PT)/international normalized ratio (INR) or aPTT &gt;1.5 times normal, but only if the patient has active and ongoing bleeding. (See <a class="local">'Plasma'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Platelets </strong>– Transfusion of platelets is reserved for patients with platelet count &lt;100,000/microL or platelet dysfunction (eg, due to residual anti-platelet drug effects) if there is clinically significant and ongoing bleeding. (See <a class="local">'Platelets'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cryoprecipitate or </strong><strong>fibrinogen concentrate</strong><strong> </strong>– We aggressively correct hypofibrinogenemia (fibrinogen &lt;150mg/dL) in patients with active bleeding. (See <a class="local">'Cryoprecipitate versus fibrinogen concentrate'</a> above.)</p><p></p><p class="bulletIndent3">In the United States and the United Kingdom, Cryoprecipitate is often used to treat hypofibrinogenemia because of its wider availability and lower cost.</p><p></p><p class="bulletIndent3">In continental Europe and Canada, <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> is preferred for treatment of hypofibrinogenemia because it has a lower risk of infection and transfusion reactions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Coagulation factor concentrates and hemostatic agents</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Prothrombin complex concentrate (PCC) </strong>– For patients with intractable coagulopathy and diffuse bleeding after CPB, or for those intolerant of high FFP transfusion volume, off-label intraoperative use of unactivated 4-factor or 3-factor PCC products is reasonable  (<a class="graphic graphic_table graphicRef94210" href="/d/graphic/94210.html" rel="external">table 3</a>). However, other causes of intractable microvascular bleeding should be treated before considering a PCC product, and PCCs are avoided in patients with prothrombotic risks. (See <a class="local">'Prothrombin complex concentrate products'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Recombinant activated factor VII (rFVIIa) </strong>– In rare instances of severe intractable life-threatening coagulopathic bleeding after CPB, off-label administration of rFVIIa has been used in attempts to achieve bleeding cessation and reduce transfusion requirements. (See <a class="local">'Recombinant activated factor VII'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Antifibrinolytic agents </strong>–<strong> </strong>If active bleeding necessitating transfusion persists, we typically continue the antifibrinolytic agent throughout the postbypass period and into the postoperative period. (See <a class="local">'Antifibrinolytic agents'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Desmopressin</strong><strong> (DDAVP) </strong>– Intravenous (IV) DDAVP 0.3 mcg/kg is administered in selected patients with acquired platelet defects due to uremia or those with acquired von Willebrand disease  (<a class="graphic graphic_table graphicRef110532" href="/d/graphic/110532.html" rel="external">table 4</a>), but only if persistent microvascular bleeding is evident. (See <a class="local">'Desmopressin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of postoperative bleeding </strong>– Close monitoring for bleeding continues in the postoperative period. Return to the operating room for surgical re-exploration is occasionally necessary based on the rate and presumed location of bleeding, as well as the surgeon’s assessment of potential for a surgical cause. (See <a class="local">'Management of bleeding and coagulopathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of postoperative anemia</strong>  (<a class="graphic graphic_algorithm graphicRef131161" href="/d/graphic/131161.html" rel="external">algorithm 2</a>) –<strong> </strong>(See <a class="local">'Management of anemia'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Shore-Lesserson L, Baker RA, Ferraris VA, et al. The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines-Anticoagulation During Cardiopulmonary Bypass. Ann Thorac Surg 2018; 105:650.</a></li><li><a class="nounderline abstract_t">Erdoes G, Faraoni D, Koster A, et al. Perioperative Considerations in Management of the Severely Bleeding Coagulopathic Patient. Anesthesiology 2023; 138:535.</a></li><li><a class="nounderline abstract_t">Sniecinski RM, Chandler WL. Activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg 2011; 113:1319.</a></li><li><a class="nounderline abstract_t">Despotis GJ, Avidan MS, Hogue CW Jr. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001; 72:S1821.</a></li><li><a class="nounderline abstract_t">Bennett-Guerrero E, Zhao Y, O'Brien SM, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA 2010; 304:1568.</a></li><li><a class="nounderline abstract_t">Raphael J, Mazer CD, Subramani S, et al. Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. Anesth Analg 2019; 129:1209.</a></li><li><a class="nounderline abstract_t">Tibi P, McClure RS, Huang J, et al. STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. Ann Thorac Surg 2021; 112:981.</a></li><li><a class="nounderline abstract_t">Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: The TRACS randomized controlled trial. JAMA 2010; 304:1559.</a></li><li><a class="nounderline abstract_t">Transfusion of Red Blood Cells, Fresh Frozen Plasma, or Platelets Is Associated With Mortality and Infection After Cardiac Surgery in a Dose-Dependent Manner. Anesth Analg 2020; 130:e32.</a></li><li><a class="nounderline abstract_t">Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91:944.</a></li><li><a class="nounderline abstract_t">Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83:S27.</a></li><li><a class="nounderline abstract_t">Dhir A, Tempe DK. Anemia and Patient Blood Management in Cardiac Surgery-Literature Review and Current Evidence. J Cardiothorac Vasc Anesth 2018; 32:2726.</a></li><li><a class="nounderline abstract_t">Pleym H, Wahba A, Videm V, et al. Increased fibrinolysis and platelet activation in elderly patients undergoing coronary bypass surgery. Anesth Analg 2006; 102:660.</a></li><li><a class="nounderline abstract_t">Biancari F, Kinnunen EM, Kiviniemi T, et al. Meta-analysis of the Sources of Bleeding after Adult Cardiac Surgery. J Cardiothorac Vasc Anesth 2018; 32:1618.</a></li><li><a class="nounderline abstract_t">Martini WZ. Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability. J Trauma 2009; 67:202.</a></li><li><a class="nounderline abstract_t">Wolberg AS, Meng ZH, Monroe DM 3rd, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004; 56:1221.</a></li><li><a class="nounderline abstract_t">Valeri CR, Khabbaz K, Khuri SF, et al. Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass. J Thorac Cardiovasc Surg 1992; 104:108.</a></li><li><a class="nounderline abstract_t">Rajagopalan S, Mascha E, Na J, Sessler DI. The effects of mild perioperative hypothermia on blood loss and transfusion requirement. Anesthesiology 2008; 108:71.</a></li><li><a class="nounderline abstract_t">Reed RL 2nd, Johnson TD, Hudson JD, Fischer RP. The disparity between hypothermic coagulopathy and clotting studies. J Trauma 1992; 33:465.</a></li><li><a class="nounderline abstract_t">Lester ELW, Fox EE, Holcomb JB, et al. The impact of hypothermia on outcomes in massively transfused patients. J Trauma Acute Care Surg 2019; 86:458.</a></li><li><a class="nounderline abstract_t">Mueller MM, Van Remoortel H, Meybohm P, et al. Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. JAMA 2019; 321:983.</a></li><li><a class="nounderline abstract_t">Curry NS, Davenport R, Pavord S, et al. The use of viscoelastic haemostatic assays in the management of major bleeding: A British Society for Haematology Guideline. Br J Haematol 2018; 182:789.</a></li><li><a class="nounderline abstract_t">Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. Eur J Anaesthesiol 2017; 34:332.</a></li><li><a class="nounderline abstract_t">American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*. Anesthesiology 2015; 122:241.</a></li><li><a class="nounderline abstract_t">Ghadimi K, Levy JH, Welsby IJ. Perioperative management of the bleeding patient. Br J Anaesth 2016; 117:iii18.</a></li><li><a class="nounderline abstract_t">Karkouti K, Callum J, Wijeysundera DN, et al. Point-of-Care Hemostatic Testing in Cardiac Surgery: A Stepped-Wedge Clustered Randomized Controlled Trial. Circulation 2016; 134:1152.</a></li><li><a class="nounderline abstract_t">Weber CF, Görlinger K, Meininger D, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117:531.</a></li><li><a class="nounderline abstract_t">Avidan MS, Alcock EL, Da Fonseca J, et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 2004; 92:178.</a></li><li><a class="nounderline abstract_t">Spalding GJ, Hartrumpf M, Sierig T, et al. Cost reduction of perioperative coagulation management in cardiac surgery: value of "bedside" thrombelastography (ROTEM). Eur J Cardiothorac Surg 2007; 31:1052.</a></li><li><a class="nounderline abstract_t">Girdauskas E, Kempfert J, Kuntze T, et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. J Thorac Cardiovasc Surg 2010; 140:1117.</a></li><li><a class="nounderline abstract_t">Hanke AA, Herold U, Dirkmann D, et al. Thromboelastometry Based Early Goal-Directed Coagulation Management Reduces Blood Transfusion Requirements, Adverse Events, and Costs in Acute Type A Aortic Dissection: A Pilot Study. Transfus Med Hemother 2012; 39:121.</a></li><li><a class="nounderline abstract_t">Karkouti K, McCluskey SA, Callum J, et al. Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery: a retrospective cohort study with interrupted time-series analysis. Anesthesiology 2015; 122:560.</a></li><li><a class="nounderline abstract_t">Görlinger K, Fries D, Dirkmann D, et al. Reduction of Fresh Frozen Plasma Requirements by Perioperative Point-of-Care Coagulation Management with Early Calculated Goal-Directed Therapy. Transfus Med Hemother 2012; 39:104.</a></li><li><a class="nounderline abstract_t">Fabbro M 2nd, Winkler AM, Levy JH. Technology: Is There Sufficient Evidence to Change Practice in Point-of-Care Management of Coagulopathy? J Cardiothorac Vasc Anesth 2017; 31:1849.</a></li><li><a class="nounderline abstract_t">Kuiper GJAJM, van Egmond LT, Henskens YMC, et al. Shifts of Transfusion Demand in Cardiac Surgery After Implementation of Rotational Thromboelastometry-Guided Transfusion Protocols: Analysis of the HEROES-CS (HEmostasis Registry of patiEntS in Cardiac Surgery) Observational, Prospective Open Cohort Database. J Cardiothorac Vasc Anesth 2019; 33:307.</a></li><li><a class="nounderline abstract_t">Irving AH, Harris A, Petrie D, et al. Impact of patient blood management guidelines on blood transfusions and patient outcomes during cardiac surgery. J Thorac Cardiovasc Surg 2020; 160:437.</a></li><li><a class="nounderline abstract_t">Le Quellec S, Bordet JC, Negrier C, Dargaud Y. Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature. Thromb Haemost 2016; 116:638.</a></li><li><a class="nounderline abstract_t">Demailly Z, Wurtz V, Barbay V, et al. Point-of-Care Viscoelastic Hemostatic Assays in Cardiac Surgery Patients: Comparison of Thromboelastography 6S, Thromboelastometry Sigma, and Quantra. J Cardiothorac Vasc Anesth 2023; 37:948.</a></li><li><a class="nounderline abstract_t">Agarwal S, Abdelmotieleb M. Viscoelastic testing in cardiac surgery. Transfusion 2020; 60 Suppl 6:S52.</a></li><li><a class="nounderline abstract_t">Wahba A, Milojevic M, Boer C, et al. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. Eur J Cardiothorac Surg 2020; 57:210.</a></li><li><a class="nounderline abstract_t">Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA), Boer C, Meesters MI, et al. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth 2018; 32:88.</a></li><li><a class="nounderline abstract_t">Raphael J, Mazer CD, Subramani S, et al. Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. J Cardiothorac Vasc Anesth 2019; 33:2887.</a></li><li><a class="nounderline abstract_t">Burns CD, Brown JP, Corwin HL, et al. Special Report From the Society for the Advancement of Blood Management: The Choosing Wisely Campaign. Anesth Analg 2019; 129:1381.</a></li><li><a class="nounderline abstract_t">Delaney M, Stark PC, Suh M, et al. Massive Transfusion in Cardiac Surgery: The Impact of Blood Component Ratios on Clinical Outcomes and Survival. Anesth Analg 2017; 124:1777.</a></li><li><a class="nounderline abstract_t">Hensley NB, Mazzeffi MA. Pro-Con Debate: Fibrinogen Concentrate or Cryoprecipitate for Treatment of Acquired Hypofibrinogenemia in Cardiac Surgical Patients. Anesth Analg 2021; 133:19.</a></li><li><a class="nounderline abstract_t">Pagano D, Milojevic M, Meesters MI, et al. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. Eur J Cardiothorac Surg 2018; 53:79.</a></li><li><a class="nounderline abstract_t">Ranucci M, Baryshnikova E, Crapelli GB, et al. Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc 2015; 4:e002066.</a></li><li><a class="nounderline abstract_t">Ghadimi K, Welsby IJ. Pro: Factor Concentrates are Essential for Hemostasis in Complex Cardiac Surgery. J Cardiothorac Vasc Anesth 2018; 32:558.</a></li><li><a class="nounderline abstract_t">Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013; 118:40.</a></li><li><a class="nounderline abstract_t">Maeda T, Miyata S, Usui A, et al. Safety of Fibrinogen Concentrate and Cryoprecipitate in Cardiovascular Surgery: Multicenter Database Study. J Cardiothorac Vasc Anesth 2019; 33:321.</a></li><li><a class="nounderline abstract_t">Li JY, Gong J, Zhu F, et al. Fibrinogen Concentrate in Cardiovascular Surgery: A Meta-analysis of Randomized Controlled Trials. Anesth Analg 2018; 127:612.</a></li><li><a class="nounderline abstract_t">Erdoes G, Koster A, Meesters MI, et al. The role of fibrinogen and fibrinogen concentrate in cardiac surgery: an international consensus statement from the Haemostasis and Transfusion Scientific Subcommittee of the European Association of Cardiothoracic Anaesthesiology. Anaesthesia 2019; 74:1589.</a></li><li><a class="nounderline abstract_t">Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30:270.</a></li><li><a class="nounderline abstract_t">Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood 2015; 125:1387.</a></li><li><a class="nounderline abstract_t">Callum J, Farkouh ME, Scales DC, et al. Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial. JAMA 2019; 322:1966.</a></li><li><a class="nounderline abstract_t">Abrahamyan L, Tomlinson G, Callum J, et al. Cost-effectiveness of Fibrinogen Concentrate vs Cryoprecipitate for Treating Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients. JAMA Surg 2023; 158:245.</a></li><li><a class="nounderline abstract_t">Galas FR, de Almeida JP, Fukushima JT, et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: a randomized pilot trial. J Thorac Cardiovasc Surg 2014; 148:1647.</a></li><li><a class="nounderline abstract_t">Bilecen S, de Groot JA, Kalkman CJ, et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial. JAMA 2017; 317:738.</a></li><li><a class="nounderline abstract_t">Rahe-Meyer N, Levy JH, Mazer CD, et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. Br J Anaesth 2016; 117:41.</a></li><li><a class="nounderline abstract_t">Smith MM, Ashikhmina E, Brinkman NJ, Barbara DW. Perioperative Use of Coagulation Factor Concentrates in Patients Undergoing Cardiac Surgery. J Cardiothorac Vasc Anesth 2017; 31:1810.</a></li><li><a class="nounderline abstract_t">Fitzgerald J, Lenihan M, Callum J, et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. Br J Anaesth 2018; 120:928.</a></li><li><a class="nounderline abstract_t">Cappabianca G, Mariscalco G, Biancari F, et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Crit Care 2016; 20:5.</a></li><li><a class="nounderline abstract_t">Ortmann E, Besser MW, Sharples LD, et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg 2015; 121:26.</a></li><li><a class="nounderline abstract_t">Arnékian V, Camous J, Fattal S, et al. Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interact Cardiovasc Thorac Surg 2012; 15:382.</a></li><li><a class="nounderline abstract_t">Roman M, Biancari F, Ahmed AB, et al. Prothrombin Complex Concentrate in Cardiac Surgery: A Systematic Review and Meta-Analysis. Ann Thorac Surg 2019; 107:1275.</a></li><li><a class="nounderline abstract_t">Smith MM, Schroeder DR, Nelson JA, et al. Prothrombin Complex Concentrate vs Plasma for Post-Cardiopulmonary Bypass Coagulopathy and Bleeding: A Randomized Clinical Trial. JAMA Surg 2022; 157:757.</a></li><li><a class="nounderline abstract_t">Ghadimi K, Levy JH, Welsby IJ. Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting. Anesth Analg 2016; 122:1287.</a></li><li><a class="nounderline abstract_t">Fries D. The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. Transfusion 2013; 53 Suppl 1:91S.</a></li><li><a class="nounderline abstract_t">Hashmi NK, Ghadimi K, Srinivasan AJ, et al. Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. Vox Sang 2019; 114:374.</a></li><li><a class="nounderline abstract_t">Karkouti K, Bartoszko J, Grewal D, et al. Comparison of 4-Factor Prothrombin Complex Concentrate With Frozen Plasma for Management of Hemorrhage During and After Cardiac Surgery: A Randomized Pilot Trial. JAMA Netw Open 2021; 4:e213936.</a></li><li><a class="nounderline abstract_t">Nemeth E, Varga T, Soltesz A, et al. Perioperative Factor Concentrate Use is Associated With More Beneficial Outcomes and Reduced Complication Rates Compared With a Pure Blood Product-Based Strategy in Patients Undergoing Elective Cardiac Surgery: A Propensity Score-Matched Cohort Study. J Cardiothorac Vasc Anesth 2022; 36:138.</a></li><li><a class="nounderline abstract_t">Song HK, Tibayan FA, Kahl EA, et al. Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery. J Thorac Cardiovasc Surg 2014; 147:1036.</a></li><li><a class="nounderline abstract_t">Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010; 8:149.</a></li><li><a class="nounderline abstract_t">Rota M, Cortesi PA, Crea R, et al. Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. Blood Adv 2017; 1:2637.</a></li><li><a class="nounderline abstract_t">Baral P, Cotter E, Gao G, et al. Characteristics Associated With Mortality in 372 Patients Receiving Low-Dose Recombinant Factor VIIa (rFVIIa) for Cardiac Surgical Bleeding. J Cardiothorac Vasc Anesth 2019; 33:2133.</a></li><li><a class="nounderline abstract_t">Sutherland L, Houchin A, Wang T, et al. Impact of Early, Low-Dose Factor VIIa on Subsequent Transfusions and Length of Stay in Cardiac Surgery. J Cardiothorac Vasc Anesth 2022; 36:147.</a></li><li><a class="nounderline abstract_t">Hessel EA 2nd. What's New in Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2019; 33:2296.</a></li><li><a class="nounderline abstract_t">Karkouti K, Beattie WS, Arellano R, et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation 2008; 118:331.</a></li><li><a class="nounderline abstract_t">Lee AI, Campigotto F, Rawn JD, et al. Clinical significance of coagulation studies in predicting response to activated recombinant Factor VII in cardiac surgery patients. Br J Haematol 2012; 157:397.</a></li><li><a class="nounderline abstract_t">Andersen ND, Bhattacharya SD, Williams JB, et al. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations. Ann Thorac Surg 2012; 93:1921.</a></li><li><a class="nounderline abstract_t">Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363:1791.</a></li><li><a class="nounderline abstract_t">Gill R, Herbertson M, Vuylsteke A, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009; 120:21.</a></li><li><a class="nounderline abstract_t">Tiede A, Rand JH, Budde U, et al. How I treat the acquired von Willebrand syndrome. Blood 2011; 117:6777.</a></li><li><a class="nounderline abstract_t">Sadler JE. Aortic stenosis, von Willebrand factor, and bleeding. N Engl J Med 2003; 349:323.</a></li><li><a class="nounderline abstract_t">Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349:343.</a></li><li><a class="nounderline abstract_t">Steinlechner B, Zeidler P, Base E, et al. Patients with severe aortic valve stenosis and impaired platelet function benefit from preoperative desmopressin infusion. Ann Thorac Surg 2011; 91:1420.</a></li><li><a class="nounderline abstract_t">Hanke AA, Dellweg C, Kienbaum P, et al. Effects of desmopressin on platelet function under conditions of hypothermia and acidosis: an in vitro study using multiple electrode aggregometry*. Anaesthesia 2010; 65:688.</a></li><li><a class="nounderline abstract_t">Ying CL, Tsang SF, Ng KF. The potential use of desmopressin to correct hypothermia-induced impairment of primary haemostasis--an in vitro study using PFA-100. Resuscitation 2008; 76:129.</a></li><li><a class="nounderline abstract_t">Desborough MJ, Oakland K, Brierley C, et al. Desmopressin use for minimising perioperative blood transfusion. Cochrane Database Syst Rev 2017; 7:CD001884.</a></li><li><a class="nounderline abstract_t">Desborough MJ, Oakland KA, Landoni G, et al. Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 2017; 15:263.</a></li><li><a class="nounderline abstract_t">de Prost D, Barbier-Boehm G, Hazebroucq J, et al. Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass. Thromb Haemost 1992; 68:106.</a></li><li><a class="nounderline abstract_t">Orlov D, McCluskey SA, Callum J, et al. Utilization and Effectiveness of Desmopressin Acetate After Cardiac Surgery Supplemented With Point-of-Care Hemostatic Testing: A Propensity-Score-Matched Analysis. J Cardiothorac Vasc Anesth 2017; 31:883.</a></li><li><a class="nounderline abstract_t">Shander A, Javidroozi M, Perelman S, et al. From bloodless surgery to patient blood management. Mt Sinai J Med 2012; 79:56.</a></li><li><a class="nounderline abstract_t">Muñoz M, Acheson AG, Bisbe E, et al. An international consensus statement on the management of postoperative anaemia after major surgical procedures. Anaesthesia 2018; 73:1418.</a></li><li><a class="nounderline abstract_t">Biancari F, Mikkola R, Heikkinen J, et al. Estimating the risk of complications related to re-exploration for bleeding after adult cardiac surgery: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2012; 41:50.</a></li><li><a class="nounderline abstract_t">Knapik P, Cieśla D, Saucha W, et al. Outcome Prediction After Coronary Surgery and Redo Surgery for Bleeding (From the KROK Registry). J Cardiothorac Vasc Anesth 2019; 33:2930.</a></li><li><a class="nounderline abstract_t">Douketis JD, Spyropoulos AC, Murad MH, et al. Executive Summary: Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest 2022; 162:1127.</a></li><li><a class="nounderline abstract_t">Zeroual N, Blin C, Saour M, et al. Restrictive Transfusion Strategy after Cardiac Surgery. Anesthesiology 2021; 134:370.</a></li><li><a class="nounderline abstract_t">Ali JM, Gerrard C, Clayton J, Moorjani N. Reduced re-exploration and blood product transfusion after the introduction of the Papworth haemostasis checklist†. Eur J Cardiothorac Surg 2019; 55:729.</a></li><li><a class="nounderline abstract_t">Matzek LJ, LeMahieu AM, Madde NR, et al. A Contemporary Analysis of Phlebotomy and Iatrogenic Anemia Development Throughout Hospitalization in Critically Ill Adults. Anesth Analg 2022; 135:501.</a></li></ol></div><div id="topicVersionRevision">Topic 122792 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29362176" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines-Anticoagulation During Cardiopulmonary Bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36862401" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Perioperative Considerations in Management of the Severely Bleeding Coagulopathic Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22003219" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Activation of the hemostatic system during cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11722116" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mechanisms and attenuation of hemostatic activation during extracorporeal circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20940382" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Variation in use of blood transfusion in coronary artery bypass graft surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613811" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34217505" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20940381" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Transfusion requirements after cardiac surgery: The TRACS randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31702696" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Transfusion of Red Blood Cells, Fresh Frozen Plasma, or Platelets Is Associated With Mortality and Infection After Cardiac Surgery in a Dose-Dependent Manner.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21353044" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17462454" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29307702" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Anemia and Patient Blood Management in Cardiac Surgery-Literature Review and Current Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16492812" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Increased fibrinolysis and platelet activation in elderly patients undergoing coronary bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29338997" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Meta-analysis of the Sources of Bleeding after Adult Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19590336" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15211129" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1614195" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18156884" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The effects of mild perioperative hypothermia on blood loss and transfusion requirement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1404519" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The disparity between hypothermic coagulopathy and clotting studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30444856" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The impact of hypothermia on outcomes in massively transfused patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30860564" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30073664" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The use of viscoelastic haemostatic assays in the management of major bleeding: A British Society for Haematology Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28459785" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25545654" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940453" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Perioperative management of the bleeding patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27654344" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Point-of-Care Hemostatic Testing in Cardiac Surgery: A Stepped-Wedge Clustered Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22914710" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14722166" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17398108" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cost reduction of perioperative coagulation management in cardiac surgery: value of "bedside" thrombelastography (ROTEM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20951260" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22670130" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Thromboelastometry Based Early Goal-Directed Coagulation Management Reduces Blood Transfusion Requirements, Adverse Events, and Costs in Acute Type A Aortic Dissection: A Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25485470" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery: a retrospective cohort study with interrupted time-series analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22670128" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Reduction of Fresh Frozen Plasma Requirements by Perioperative Point-of-Care Coagulation Management with Early Calculated Goal-Directed Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28844370" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Technology: Is There Sufficient Evidence to Change Practice in Point-of-Care Management of Coagulopathy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30269889" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Shifts of Transfusion Demand in Cardiac Surgery After Implementation of Rotational Thromboelastometry-Guided Transfusion Protocols: Analysis of the HEROES-CS (HEmostasis Registry of patiEntS in Cardiac Surgery) Observational, Prospective Open Cohort Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31711621" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Impact of patient blood management guidelines on blood transfusions and patient outcomes during cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27440202" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36931905" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Point-of-Care Viscoelastic Hemostatic Assays in Cardiac Surgery Patients: Comparison of Thromboelastography 6S, Thromboelastometry Sigma, and Quantra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32955756" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Viscoelastic testing in cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31576396" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29029990" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31604540" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31517679" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Special Report From the Society for the Advancement of Blood Management: The Choosing Wisely Campaign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28333704" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Massive Transfusion in Cardiac Surgery: The Impact of Blood Component Ratios on Clinical Outcomes and Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34127586" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pro-Con Debate: Fibrinogen Concentrate or Cryoprecipitate for Treatment of Acquired Hypofibrinogenemia in Cardiac Surgical Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29029100" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26037084" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29217233" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pro: Factor Concentrates are Essential for Hemostasis in Complex Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23249928" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30057251" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Safety of Fibrinogen Concentrate and Cryoprecipitate in Cardiovascular Surgery: Multicenter Database Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29863608" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Fibrinogen Concentrate in Cardiovascular Surgery: A Meta-analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31531856" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The role of fibrinogen and fibrinogen concentrate in cardiac surgery: an international consensus statement from the Haemostasis and Transfusion Scientific Subcommittee of the European Association of Cardiothoracic Anaesthesiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23656742" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25519751" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : How I use fibrinogen replacement therapy in acquired bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31634905" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36598773" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cost-effectiveness of Fibrinogen Concentrate vs Cryoprecipitate for Treating Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24951020" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: a randomized pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28241354" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27317703" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28838728" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Perioperative Use of Coagulation Factor Concentrates in Patients Undergoing Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29661410" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26738468" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25822921" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22623627" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30458156" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prothrombin Complex Concentrate in Cardiac Surgery: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767271" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prothrombin Complex Concentrate vs Plasma for Post-Cardiopulmonary Bypass Coagulopathy and Bleeding: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26983050" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23301979" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30937927" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33792729" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Comparison of 4-Factor Prothrombin Complex Concentrate With Frozen Plasma for Management of Hemorrhage During and After Cardiac Surgery: A Randomized Pilot Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33941446" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Perioperative Factor Concentrate Use is Associated With More Beneficial Outcomes and Reduced Complication Rates Compared With a Pure Blood Product-Based Strategy in Patients Undergoing Elective Cardiac Surgery: A Propensity Score-Matched Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24365268" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20671873" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prothrombin complex concentrates: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29296916" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30772178" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Characteristics Associated With Mortality in 372 Patients Receiving Low-Dose Recombinant Factor VIIa (rFVIIa) for Cardiac Surgical Bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34103218" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Impact of Early, Low-Dose Factor VIIa on Subsequent Transfusions and Length of Stay in Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30928282" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : What's New in Cardiopulmonary Bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18606914" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22224596" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical significance of coagulation studies in predicting response to activated recombinant Factor VII in cardiac surgery patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22551846" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21047223" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Safety of recombinant activated factor VII in randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19546387" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21540459" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : How I treat the acquired von Willebrand syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12878737" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Aortic stenosis, von Willebrand factor, and bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12878741" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Acquired von Willebrand syndrome in aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21439546" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Patients with severe aortic valve stenosis and impaired platelet function benefit from preoperative desmopressin infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20477783" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effects of desmopressin on platelet function under conditions of hypothermia and acidosis: an in vitro study using multiple electrode aggregometry*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17714852" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The potential use of desmopressin to correct hypothermia-induced impairment of primary haemostasis--an in vitro study using PFA-100.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28691229" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Desmopressin use for minimising perioperative blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27893176" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1412152" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28169116" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Utilization and Effectiveness of Desmopressin Acetate After Cardiac Surgery Supplemented With Point-of-Care Hemostatic Testing: A Propensity-Score-Matched Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22238039" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : From bloodless surgery to patient blood management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30062700" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : An international consensus statement on the management of postoperative anaemia after major surgical procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21640602" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Estimating the risk of complications related to re-exploration for bleeding after adult cardiac surgery: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31281012" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Outcome Prediction After Coronary Surgery and Redo Surgery for Bleeding (From the KROK Registry).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35964703" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Executive Summary: Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33475735" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Restrictive Transfusion Strategy after Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30346507" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Reduced re-exploration and blood product transfusion after the introduction of the Papworth haemostasis checklist†.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35977360" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A Contemporary Analysis of Phlebotomy and Iatrogenic Anemia Development Throughout Hospitalization in Critically Ill Adults.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
